Adhesive Capsulitis Moves From Painful Inflammation to Fibrotic Shoulder Stiffness
Adhesive capsulitis remains one of the most common reasons a shoulder becomes painful and progressively immobile without a clear structural injury. The condition, often called frozen shoulder, affects an estimated 2% to 5% of the population and appears more often in women, in adults between 40 and 60 years of age, and in people with diabetes. In practice, it is not just a pain syndrome. It is a disorder of a joint capsule that gradually tightens, thickens, and loses elasticity until ordinary shoulder motion becomes mechanically restricted.
The burden is easy to underestimate until the loss of motion becomes functionally obvious. Reaching overhead, dressing, fastening a bra, or rotating the arm outward can become difficult long before imaging explains why.
Synovial Inflammation and Capsular Fibrosis Drive the Disease Process
Current understanding places synovial inflammation at the center of early disease, followed by progressive capsular fibrosis and neovascularization. The biologic sequence matters because the shoulder does not simply become sore; it becomes scarred. Inflammatory mediators including transforming growth factor beta, interleukin-1 beta, and tumor necrosis factor alpha contribute to synovial hyperplasia and the fibrotic remodeling that defines the disorder.
Histology adds another layer. The capsule contains highly cellular vascular and collagenous tissue with fibroblasts and myofibroblasts, a pattern that resembles other fibroproliferative disorders. The overlap with Dupuytren disease is especially notable, both because of the shared fibrotic biology and because abnormal matrix metalloproteinase regulation may help explain why collagen becomes difficult to remodel once the process starts. Diabetes may intensify this biology through accelerated glycosylation and cross-linking of collagen, making the capsule stiffer and less forgiving.
Neovascularization is not a passive bystander. Vascular endothelial growth factor has been identified in frozen shoulder synovium, including in diabetic patients, reinforcing the idea that the disorder is both inflammatory and fibrovascular rather than purely mechanical.
Staged Clinical Progression Shapes Diagnosis and Treatment Expectations
Clinicians usually describe adhesive capsulitis in three stages: freezing, frozen, and thawing. Each stage carries a different balance of pain and stiffness, and each stage implies a different therapeutic target. Early disease tends to be pain dominant, while later disease becomes a problem of restriction, contracture, and disability.
External rotation and abduction are commonly the first and most limited movements. The rotator interval, coracohumeral ligament, anterior capsule, and inferior capsule all play a role in the motion block. When these structures contract, the shoulder loses the small but essential degrees of freedom needed for normal daily function. Release of the coracohumeral ligament can restore external rotation, which fits the anatomical pattern seen at the bedside.
Diabetes and Other Comorbidities Mark a More Difficult Course
Adhesive capsulitis is often idiopathic, but the review places clear emphasis on associated conditions. Diabetes, prior trauma or surgery, cardiac disease, endocrine and metabolic disorders, neurological disease, and other fibroproliferative conditions all appear in the clinical mix. The link is not fully explained, yet the repeated association suggests shared vulnerability in tissue repair and collagen regulation.
Patients with diabetes deserve special attention. Their risk of developing adhesive capsulitis is higher, and therapeutic response may be less robust. Post-traumatic cases also tend to do worse than idiopathic or post-surgical presentations. In a busy clinic, those distinctions alter expectations early, before patients interpret slow improvement as treatment failure.
Conservative Care Remains the First-Line Approach for Most Patients
Initial management typically starts with nonoperative therapy. Physical therapy, nonsteroidal anti-inflammatory drugs, corticosteroid injections, and manipulation under anesthesia make up the core conservative toolkit. These approaches are not interchangeable. Early pain control can make exercise tolerable, while supervised mobilization attempts to preserve or restore motion before the capsule becomes more fixed.
Corticosteroid injections are most biologically plausible during the inflammatory phase, when synovitis and pain are prominent. Physical therapy becomes more central when stiffness dominates. Manipulation under anesthesia can break up adhesions and stretch contracted tissue, but it also carries the usual procedural tradeoffs of transient pain, risk of injury, and variable durability.
For many patients, time itself remains part of the treatment trajectory. Symptoms often improve eventually, but the interval can be long enough to disrupt work, sleep, and self-care well before recovery begins.
Hydrodilatation and Arthroscopic Release Address Recalcitrant Cases
When symptoms persist beyond 9 to 12 months, more invasive options become relevant. Ultrasound-guided hydrodilatation has gained attention, particularly capsule-preserving techniques that aim to enlarge the joint space without causing avoidable damage. The appeal is straightforward: mechanically distend a contracted capsule and reduce pain while preserving native structures.
Arthroscopic release is reserved for more refractory disease and offers rapid pain relief and meaningful range-of-motion gains. The operation directly addresses the contracted capsule, making it the most anatomically targeted intervention in the treatment sequence. Long-term success has been demonstrated in clinical studies, although postoperative pain can recur and may still require corticosteroid injection.
Here the disease biology and the treatment logic line up closely. A fibrotic capsule will not respond to anti-inflammatory therapy alone once mechanical contracture becomes established. At that stage, the shoulder often needs either distension, release, or both.
Stage-Based Management Still Lacks a Disease-Modifying Strategy
The review makes one point especially clear: present care is effective for many patients, but it is still largely reactive rather than disease-modifying. Management is guided by symptoms, stage, and functional limitation rather than by a proven therapy that interrupts the underlying fibrotic cascade. That leaves a major gap between understanding the biology and changing its course.
Future work needs to move beyond symptom control toward mechanism-based intervention. Better definition of the initiating trigger, clearer staging biomarkers, and therapies that target synovial inflammation before fibrosis becomes fixed would all improve care. The most useful next step is not simply another way to stretch a stiff shoulder. It is a treatment strategy that prevents the capsule from reaching that point in the first place.
For now, adhesive capsulitis remains a condition in which diagnosis is clinical, pathophysiology is increasingly coherent, and treatment still depends on matching the intervention to the stage of disease, the patient’s comorbidities, and the persistence of functional loss.